Citi Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Tweet Send to a Friend
Citi analyst David Lebowitz reiterated a Buy rating and $67.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst comments "BridgeBio ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
